NONMEM Users Network Archive

Hosted by Cognigen

Open Postdoc position at FU Berlin

From: Robin Michelet <robin.michelet>
Date: Tue, 1 Dec 2020 15:26:13 +0100

The Department of Clinical Pharmacy and Biochemistry of the Institute of
Pharmacy at the Freie Universitaet Berlin is currently looking for a:


        *Postdoctoral Research Fellow (m/f/d)*

We are an interdisciplinary, international, research-oriented group
applying high scientific standards and innovative methodologies with the
ultimate aim to foster the rational use of medicines while empowering
young scientists to perform clinically relevant research
(http://www.clinical-pharmacy.eu/ <http://www.clinical-pharmacy.eu/>).

Our group is grounded on two research pillars: (1) Bioanalysis,
microdialysis, cell culture, and (2) Pharmacometric (data) analysis. As
key feature, the two pillars are bridged, as our pharmacometric projects
are based on in vivo or in vitro data obtained by the experimental
research pillar, while innovative dynamic in vitro systems utilise
modelling and simulation approaches. In addition, many of our projects
are realised as parts of clinical studies. Typically, our research is
embedded in consortia at a national and international level (EU, global).

We are looking for a full-time postdoctoral fellow in the field of
optimising drug therapy and drug development by applying innovative
translational modelling and simulation techniques to join our research
group for a period of at least 2 years; extension to 5 years is
possible. To be eligible for the positions, a PhD and a strong record in
the pharmacometric research area is needed. Additionally, experience in
either or (i) evaluating pharmacokinetic, pharmacodynamic or systems
pharmacology data and pharmacometric analysis with NONMEM, R or similar
pharmacometric software, (ii) Bayesian analysis using STAN or similar
platforms, or (iii) one of our experimental platforms (LC/MS-MS,
microdialysis, bacterial infection models, in vitro metabolism) is
required. The positions also offer supervision of PhD and Master/Diploma
students.

Applications in English should include a letter of motivation along with
a description of research interests and relevant qualifications for the
position. In addition, a curriculum vitae including a list of
publications and names/email addresses of 2-3 referees should be
provided. Please submit your application to:
charlotte.kloft
robin.michelet
<mailto:charlotte.kloft


      Project summary

Currently, respiratory tract infections represent the third leading
cause of death worldwide (about 3 million deaths per year). Bacterial
pneumonia (either community-or hospital-acquired) is a leading cause of
morbidity, quality-adjusted life year loss, and mortality in children,
adults, and the elderly. In Europe, pneumonia costs €10 billion each
year. Although antibiotics have transformed the management and treatment
of bacterial pneumonia, their effectiveness is declining -because of
antimicrobial resistance (AMR). The World Health Organization (WHO)
estimates that bacterial infections due to AMR will outcompete any cause
of death by 2050, meaning that it is crucial to develop new strategies
to improve antibacterial treatment. In 2017, the WHO defined a priority
list of bacteria for which new antibacterial therapies are urgently
needed; it includes the major pneumonia-causing pathogens Pseudomonas
aeruginosa, Klebsiella pneumoniae, and Streptococcus pneumonia.

The FAIR project (European grant H2020 -call SC1-BHC-14-2019) proposes a
unique approach: aerosol delivery of an immunomodulatory protein (by
nebulization), achieving direct release into the airways, prompting
innate immunity activation in the lungs and preventing systemic immune
activation. FAIR’s objectives are to:

  * develop nebulization modalities for optimal airway targeting and
    rapid action at the infection site
  * demonstrate that nebulized flagellin strengthens the response to
    antibiotics in relevant preclinical models of antibiotic-resistant
    pneumonia
  * identify host immune factors required for the gain of protection
    with systems biology
  * implement pharmacokinetics/pharmacodynamics model-based design and
    simulation for clinical validation
  * assess nebulized flagellin’s safety in a Phase I clinical trial.
  * analyze the acceptability and economic relevance of the therapy
  * identify stratification markers that predict the course of pneumonia
    and treatment in antibiotic-treated cohorts.

The responsibility of work package 5 is to refine the preclinical
experiments in cell-based and animal models (WP2, WP3, and WP4) by
developing a PK/PD modelling and simulation, "ModSim" platform based on
a combination of nonlinear mixed-effects (NLME) and
physiologically-based (PB) modelling approaches (the ‘middle-out’
approach). This platform will be combined with a translational
statistical model, in order to evaluate the dose-response relationship
and enable dose-finding for the Phase I clinical trial (WP6) and the
characterisation of the biologic’s safety and PK profile in humans.
Please visit our website, https://www.clinical-pharmacy.eu
<https://www.clinical-pharmacy.eu> for more information. The project is
included in a research grant program “FAIR” (https://fair-flagellin.eu/
<https://fair-flagellin.eu/>) gathering European teams and coordinated
by J.C Sirard, Inserm,Lille, France.


      Job profile

  * Performance and publication of research projects in pharmacometric
    and translational modelling
  * Contribution to EU project “FAIR” of the Horizon 2020 initiative (11
    European partners from 6 different countries; Work package 5:
    Development of a translational modelling and simulation platform for
    flagellin PK/PD)
  * Contribution to conception and realisation of new research ideas and
    collaborations
  * General services in research (co-supervision of junior members;
    IT/Cluster contact) and research organisation


      Qualification profile

*Requirements:*

  * Graduation in Pharmaceutical or Life sciences or related field
  * Qualified PhD thesis in Pharmacometrics, systems pharmacology or
    PBPK modelling, preferentially PK/PD modelling of therapeutic proteins

*Assets:*

 1.  Profound knowledge in pharmacometrics software: e.g. NONMEM/PsN,
    Berkeley-Madonna, Monolix, nlmxR or similar
 2. Good knowledge in the software programs R, PKSim, STAN, Pirana or
    similar
 3. In-depth experience in organisation and performance of research
    projects and in scientific publication in the area of pharmacometrics
 4. Experience with or interest for in vitro work such as bacterial
    infection models, in vitro microdialysis or in vitro metabolism
    experiments.
 5. High intrinsic motivation/high level of commitment
 6. Excellent team player
 7. Strong verbal/written communication skills
 8. Language skills: English excellent

--
Dr. ir. Robin Michelet
Senior scientist

Freie Universitaet Berlin
Institute of Pharmacy
Dept. of Clinical Pharmacy & Biochemistry
Kelchstr. 31
12169 Berlin
Germany
Phone: + 49 30 838 50659
Fax: + 49 30 838 4 50656
Email: robin.michelet
www.clinical-pharmacy.eu
https://fair-flagellin.eu/


Received on Tue Dec 01 2020 - 09:26:13 EST

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to: nmusers-request@iconplc.com.

Once subscribed, you may contribute to the discussion by emailing: nmusers@globomaxnm.com.